Skip to main content

20-06-2017 | Small-cell lung cancer | Article

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Faivre-Finn C et al. Lancet Oncol 2017; 18(8): 1116-1125. doi:10.1016/S1470-2045(17)30318-2

Please log in to get access to this content

Related topics

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits